Supplementary: Table 1: Characteristics of Included Studies

Author(year)	Study	Externally	Source population and data	Reported model
	design	validated	collection period for external	performance
		equation	validation	measures
Schiborn C et al.	Prospective	EPIC-Potsdam	Germany-Heidelberg (1994	c-statistics,
2021 ¹ .	cohort	clinical and	to 2012) ¹² .	calibration plots,
		non-clinical ¹ .		and expected-to-
				observed ratios
	Prospective	D'Agostino	Germany-Potsdam and	c-statistics,
	cohort	Framingham	Germany-Heidelberg (1994	calibration plots,
		laboratory-	to 2012) ¹² .	and expected-to-
		based and		observed ratios
		non-		
		laboratory-		
		based ³ .		
Albarqouni L et al.	Prospective	D'Agostino	Australia (1999 to 2011) ⁵ .	c-statistics,
2019 ⁴ .	cohort	Framingham		calibration plots
		laboratory-		
		based and		
		non-		
		laboratory-		
		based ³ .		
Al-Shamsi S et al.	Retrospectiv	D'Agostino	United Arab Emirates	c-statistics and
2022 ⁶ .	e cohort	Framingham	(2008 to 2019) ⁶ .	calibration plots
		laboratory-		
		based and		
		non-		
		laboratory-		
		based ³ .		
Kariuki JK et al 2017	Prospective	D'Agostino	USA (1987 to 2001) 78	c-statistics,

1

7.	cohort	Framingham		calibration chi-
		laboratory-		square, and
		based and		calibration plots
		non-		
		laboratory-		
		based ³		
Joseph P et al (2018)	Prospective	INTERHEART	Africa, China, the Middle	c-statistics,
9.	cohort	laboratory-	East, North America,	calibration slop,
		based and	Europe, South America,	and calibration plot
		non-	South Asia, and Southeast	
		laboratory-	Asia: a total of 17 cohorts	
		based ¹⁰ .	were included 4 in	
			Europe/North America	
			(Canada, Poland, Sweden,	
			and Turkey); 4 in South	
			America (Argentina, Brazil,	
			Chile, and Colombia); 3 in	
			South Asia (India, Pakistan,	
			and Bangladesh); 2 in the	
			Middle East (Iran and the	
			United Arab Emirates); 1 in	
			China; 1 in Southeast Asia	
			(Malaysia); and 2 in Africa	
			(South Africa and	
			Zimbabwe).	
Hassannejad R et al	Prospective	PARS ¹² ,	Iran (2001 to 2011)	c-statistics,
(2021) ¹¹ .	cohort	SPARS ¹³		calibration chi2,
				and calibration plot

Ueda, P et al. 2017	Prospective	Ueda Globo	Australia,	c-statistics
14.	cohort	risk extension	Iran, Scotland,	
		14 .	(1984-2012)	
	Durantin	MILIO 0040 ¹⁵	There are to a herite O're	
WHO 2019 ¹⁰ .	Prospective	WHO 2019 ¹⁰ .	There were 19 conorts: 2 in	C-Statistics
	cohort		Australia, 6 in China, 4 in	
			Japan, 2 in Singapore, 2 in	
			New Zealand, 1 in Iran, 1 in	
			Thailand, and 1 in the UK.	
			The cohorts included those	
			from the Asia Pacific Cohort	
			Studies Collaboration	
			(APCSC) ¹⁶ , the New	
			Zealand primary care-based	
			PREDICT cardiovascular	
			disease cohort	
			(PREDICTCVD) ¹⁷ , the	
			Chinese Multi-Provincial	
			Cohort Study ¹⁸ , the Health	
			Checks Ubon Ratchathani	
			Study in Thailand ¹⁹ , the	
			Tehran Lipids and Glucose	
			Study ²⁰ , and the UK	
			Biobank ²¹ .	
Li J et al. 2021 ²² .	Prospective	WHO 2019 ¹⁵ .	China-PAR Cohort from	c-statistics and
	cohort		1992 to 2015 ²² .	calibration chi-
				square

EPIC: European Prospective Investigation into Cancer and Nutrition: PARS: Persian Atherosclerotic Cardiovascular Disease Risk Stratification: SPARS: Simplified Non-Laboratory-Based PARS: China-PAR: Prediction for Atherosclerotic Cardiovascular Disease Risk in China.

3

References

- Schiborn C, Kühn T, Mühlenbruch K, et al. A newly developed and externally validated nonclinical score accurately predicts 10-year cardiovascular disease risk in the general adult population. Sci Rep 2021;11(1):19609. doi: 10.1038/s41598-021-99103-4 [published Online First: 20211004]
- Bergmann MM, Bussas U, Boeing H. Follow-up procedures in EPIC-Germany--data quality aspects. European Prospective Investigation into Cancer and Nutrition. Ann Nutr Metab 1999;43(4):225-34. doi: 10.1159/000012789
- D'Agostino RB, Sr., Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008;117(6):743-53. doi: 10.1161/circulationaha.107.699579 [published Online First: 20080122]
- Albarqouni L, Doust JA, Magliano D, et al. External validation and comparison of four cardiovascular risk prediction models with data from the Australian Diabetes, Obesity, and Lifestyle study. Medical Journal of Australia 2019;210(4):161-67. doi: https://doi.org/10.5694/mja2.12061
- Dunstan DW, Zimmet PZ, Welborn TA, et al. The Australian Diabetes, Obesity and Lifestyle Study (AusDiab)--methods and response rates. Diabetes Res Clin Pract 2002;57(2):119-29. doi: 10.1016/s0168-8227(02)00025-6
- Al-Shamsi S, Govender RD, King J. External validation and clinical usefulness of three commonly used cardiovascular risk prediction scores in an Emirati population: a retrospective longitudinal cohort study. BMJ Open 2020;10(10):e040680. doi: 10.1136/bmjopen-2020-040680 [published Online First: 20201028]
- Kariuki JK, Stuart-Shor EM, Leveille SG, et al. Validation of the nonlaboratory-based Framingham cardiovascular disease risk assessment algorithm in the Atherosclerosis Risk in Communities dataset. Journal of Cardiovascular Medicine 2017;18:936–45.
- The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators. Am J Epidemiol 1989;129(4):687-702.
- Joseph P, Yusuf S, Lee SF, et al. Prognostic validation of a non-laboratory and a laboratory based cardiovascular disease risk score in multiple regions of the world. Heart 2018;104(7):581-87. doi: 10.1136/heartjnl-2017-311609 [published Online First: 20171024]

- McGorrian C, Yusuf S, Islam S, et al. Estimating modifiable coronary heart disease risk in multiple regions of the world: the INTERHEART Modifiable Risk Score. Eur Heart J 2011;32(5):581-9. doi: 10.1093/eurheartj/ehq448 [published Online First: 20101222]
- Hassannejad R, Mansourian M, Marateb H, et al. Developing Non-Laboratory Cardiovascular Risk Assessment Charts and Validating Laboratory and Non-Laboratory-Based Models. Glob Heart 2021;16(1):58. doi: 10.5334/gh.890 [published Online First: 20210902]
- Sarrafzadegan N, Hassannejad R, Marateb HR, et al. PARS risk charts: A 10-year study of risk assessment for cardiovascular diseases in Eastern Mediterranean Region. PLoS One 2017;12(12):e0189389. doi: 10.1371/journal.pone.0189389
- Hassannejad R, Mansourian M, Marateb H, et al. Developing Non-Laboratory Cardiovascular Risk Assessment Charts and Validating Laboratory and Non-Laboratory-Based Models. Global Heart 2021;16(1):58-58. doi: 10.5334/gh.890
- Ueda P, Woodward M, Lu Y, et al. Laboratory-based and office-based risk scores and charts to predict 10-year risk of cardiovascular disease in 182 countries: a pooled analysis of prospective cohorts and health surveys. Lancet Diabetes Endocrinol 2017;5(3):196-213. doi: 10.1016/s2213-8587(17)30015-3 [published Online First: 20170124]
- Group WCRCW. World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions. The Lancet Global Health 2019;7(10):e1332-e45. doi: 10.1016/S2214-109X(19)30318-3 [published Online First: 2019/09/02]
- 16. Woodward M, Huxley R, Ueshima H, et al. The Asia Pacific cohort studies collaboration: a decade of achievements. Glob Heart 2012;7(4):343-51. doi: 10.1016/j.gheart.2012.10.001 [published Online First: 20121205]
- Pylypchuk R, Wells S, Kerr A, et al. Cardiovascular disease risk prediction equations in 400 000 primary care patients in New Zealand: a derivation and validation study. Lancet 2018;391(10133):1897-907. doi: 10.1016/s0140-6736(18)30664-0 [published Online First: 20180504]

5

- Wang Y, Liu J, Wang W, et al. The lifetime risk for cardiovascular disease in a Chinese population: the Chinese Multi-Provincial Cohort Study. Eur J Prev Cardiol 2015;22(3):380-8. doi: 10.1177/2047487313516563 [published Online First: 20131211]
- Suebsamran P, Choenchoopon H, Rojanasaksothorn S, et al. Association between Alcohol Consumption and Pre-Diabetes among 383,442 Thai Population Aged 15 Years and Older in Ubon Ratchathani: Analytical Cross-Sectional Study. J Med Assoc Thai 2016;99 Suppl 1:S35-42.
- Khalili D, Hadaegh F, Soori H, et al. Clinical usefulness of the Framingham cardiovascular risk profile beyond its statistical performance: the Tehran Lipid and Glucose Study. Am J Epidemiol 2012;176(3):177-86. doi: 10.1093/age/kws204 [published Online First: 20120719]
- 21. Sudlow C, Gallacher J, Allen N, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med 2015;12(3):e1001779. doi: 10.1371/journal.pmed.1001779 [published Online First: 20150331]
- 22. Li J, Liu F, Yang X, et al. Validating World Health Organization cardiovascular disease risk charts and optimizing risk assessment in China. The Lancet Regional Health - Western Pacific 2021;8:100096. doi: https://doi.org/10.1016/j.lanwpc.2021.100096